Table 4.
Condition | Source | Study Phase | Participant Number | Route | Study Location | NCT Number |
---|---|---|---|---|---|---|
ARDS | BM | 1/2 | 169 | Inhalation | China | NCT04602104 |
Lung diseases | N.A | 1 | 27 | Inhalation | China | NCT04313647 |
COVID-19 | N.A | 1/2 | 30 | Inhalation | Russian | NCT04491240 |
BPD | BM | 1 | 18 | Intravenous | USA | NCT03857841 |
COVID-19 | BM | 1 | 24 | Inhalation | China | NCT04276987 |
MODS | UC | N.A | 60 | Intravenous | China | NCT04356300 |
Drug-Resistant | AT | 1/2 | 60 | Intravenous | China | NCT04544215 |
Chronic wounds | WJ | 1 | 38 | Topical | Indonesia | NCT04134676 |
Ischemic stroke | N.A | 1/2 | 5 | Intravenous | Iran | NCT03384433 |
Dry eye | UC | 1/2 | 27 | Eye Drops | China | NCT04213248 |
Macular holes | UC | Early 1 | 44 | Eye Drops | China | NCT03437759 |
AD | AT | 1/2 | 9 | Nasal Drops | China | NCT04388982 |
EB | BM | 1/2 | 10 | Topical | NA | NCT04173650 |
Bone marrow (BM), Adipose tissue (AT), Wharton’s jelly (WJ), Umbilical cord (UC), Coronavirus disease 2019 (COVID-19), Bronchopulmonary dysplasia (BPD), Alzheimer’s diseases (AD), Acute respiratory distress syndrome (ARDS), Epidermolysis bullosa (EB), Multiple organ dysfunction syndromes (MODS), Not available (N.A)